HC Wainwright Reaffirms Buy Rating for Compass Therapeutics (NASDAQ:CMPX)

Compass Therapeutics (NASDAQ:CMPX)‘s stock had its “buy” rating reaffirmed by stock analysts at HC Wainwright in a research note issued to investors on Monday,Benzinga reports. They presently have a $24.00 price target on the stock.

Several other analysts also recently weighed in on the company. Wedbush restated an “outperform” rating and set a $8.00 target price on shares of Compass Therapeutics in a research note on Tuesday, April 1st. Leerink Partners upgraded Compass Therapeutics from a “market perform” rating to an “outperform” rating and increased their target price for the company from $4.00 to $6.00 in a research note on Wednesday, April 2nd. D. Boral Capital restated a “buy” rating and issued a $32.00 price target on shares of Compass Therapeutics in a research note on Monday. Jefferies Financial Group increased their price objective on shares of Compass Therapeutics from $7.00 to $8.00 and gave the company a “buy” rating in a research note on Monday, February 10th. Finally, Piper Sandler started coverage on shares of Compass Therapeutics in a research note on Wednesday, February 19th. They issued an “overweight” rating and a $12.00 target price on the stock. Eight investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Compass Therapeutics presently has an average rating of “Buy” and an average price target of $13.38.

Compass Therapeutics Price Performance

Shares of CMPX stock remained flat at $1.75 during trading hours on Monday. The stock had a trading volume of 428,079 shares, compared to its average volume of 862,932. The stock has a market capitalization of $242.00 million, a P/E ratio of -4.73 and a beta of 1.40. Compass Therapeutics has a fifty-two week low of $0.77 and a fifty-two week high of $4.08. The company’s fifty day simple moving average is $2.37 and its two-hundred day simple moving average is $2.10.

Compass Therapeutics (NASDAQ:CMPX) last issued its quarterly earnings data on Thursday, February 27th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by ($0.01). Research analysts forecast that Compass Therapeutics will post -0.36 earnings per share for the current year.

Insider Activity

In other Compass Therapeutics news, Director Carl L. Gordon sold 3,571,428 shares of the firm’s stock in a transaction on Wednesday, April 9th. The stock was sold at an average price of $1.59, for a total value of $5,678,570.52. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Jonathan Anderman purchased 20,000 shares of the stock in a transaction dated Monday, April 7th. The shares were purchased at an average price of $1.54 per share, with a total value of $30,800.00. Following the transaction, the insider now directly owns 21,000 shares of the company’s stock, valued at approximately $32,340. The trade was a 2,000.00 % increase in their position. The disclosure for this purchase can be found here. Corporate insiders own 28.50% of the company’s stock.

Institutional Trading of Compass Therapeutics

Several large investors have recently added to or reduced their stakes in the business. Rhumbline Advisers increased its holdings in shares of Compass Therapeutics by 3.1% during the fourth quarter. Rhumbline Advisers now owns 129,116 shares of the company’s stock valued at $187,000 after purchasing an additional 3,822 shares during the period. Invesco Ltd. lifted its stake in shares of Compass Therapeutics by 11.3% in the 4th quarter. Invesco Ltd. now owns 39,483 shares of the company’s stock worth $57,000 after acquiring an additional 4,018 shares during the period. Bank of New York Mellon Corp boosted its holdings in shares of Compass Therapeutics by 2.6% in the fourth quarter. Bank of New York Mellon Corp now owns 237,975 shares of the company’s stock valued at $345,000 after acquiring an additional 6,041 shares in the last quarter. ProShare Advisors LLC increased its stake in shares of Compass Therapeutics by 49.0% during the fourth quarter. ProShare Advisors LLC now owns 28,722 shares of the company’s stock valued at $42,000 after acquiring an additional 9,451 shares during the period. Finally, Price T Rowe Associates Inc. MD lifted its position in Compass Therapeutics by 31.8% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 46,942 shares of the company’s stock worth $69,000 after purchasing an additional 11,326 shares during the period. 68.43% of the stock is currently owned by institutional investors and hedge funds.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.